ChemotherapyFDA-approvedFirst-line
Adriamycin (Doxorubicin)
Generic name: doxorubicin
How it works
Interferes with DNA replication and cell division, causing cancer cells to die.
Cancer types
Breast Cancer— All patients
Efficacy
In clinical trials, around 30% of patients achieved an objective response, with median overall survival of approximately 24 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Understanding Resistance to Doxorubicin in Triple-Negative Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Detecting Cancer Drug Concentration in Cells | Breast Cancer | lab-study | — | Source → |
| Long non-coding RNA STMN1P2 linked to breast cancer resistance to doxorubicin | Breast Cancer | lab-study | — | Source → |
| New Compound Shows Promise in Treating Prostate Cancer | Prostate Cancer | lab-study | — | Source → |
| Dichloroacetate Enhances Chemotherapy Effectiveness in Some Breast Cancer Cells | Breast Cancer | lab-study | The cell line MCF7 exhibited the highest rate of inhibition, followed by MDA-MB-231 and T47D. | Source → |
| Doxorubicin's kidney damage linked to SIRT1/HSF1 pathway | Ovarian Cancer | animal-study | — | Source → |
| Ovarian Cancer and Heart Damage: New Research and Treatment Strategies | Ovarian Cancer | review | — | Source → |
| Targeting Prion Protein to Overcome Chemotherapy Resistance in Lung Cancer | Lung Cancer | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.